
In today’s ACT Brief, we examine how AI can cut coordinator screening time, how participants respond to AI-assisted pre-screening, and how FDA approved three new treatments.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.






